BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zetia (Ezetimibe) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zetia (Ezetimibe)\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04701242-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zetia (Ezetimibe): Phase na readout est. (NCT04701242)
DESCRIPTION:Zetia (Ezetimibe)\, phase na\, Atherosclerotic Cardiovascular D
 isease.\nStudy: Ezetimibe Utilization Early After Acute Myocardial Infarct
 ion\, "EzAMI Trial"\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ezetimibe#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04701242
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839741-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT07839741)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4\, Atherosclerotic Cardiovascular Di
 sease.\nStudy: LDL Cholesterol Reduction Following Ezetimibe Initiation\nE
 stimated primary completion: January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ezetimibe#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07839741
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05641753-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT05641753)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4.\nStudy: Cholesterol Lowering and R
 esidual Risk in Diabetes\, Type 1\nEstimated primary completion: 1 July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ezetimibe#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05641753
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782777-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zetia (Ezetimibe): Phase na readout est. (NCT05782777)
DESCRIPTION:Zetia (Ezetimibe)\, phase na\, Atherosclerotic Cardiovascular D
 isease.\nStudy: Effect of High-intensity Statin With Ezetimibe COmbination
  theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coron
 ary Intervention With Drug-eluting Stents\; the ESCORT Trial\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ezetimibe#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05782777
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06437574-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zetia (Ezetimibe): Phase 2 readout est. (NCT06437574)
DESCRIPTION:Zetia (Ezetimibe)\, phase 2.\nStudy: Intensive Cholesterol-Lowe
 ring and CD8+ T Cells in Prostate Cancer\nEstimated primary completion: 29
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ezeti
 mibe#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06437574
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824323-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT07824323)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4\, Atherosclerotic Cardiovascular Di
 sease.\nStudy: Early Triple Lipid-Lowering Therapy With Bempedoic Acid Aft
 er Acute Coronary Syndrome\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ezetimibe#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07824323
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752758-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT07752758)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4.\nStudy: Ezetimibe for Arrhythmia R
 ecurrence After AF Ablation\nEstimated primary completion: 1 June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ezetimibe#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07752758
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07626840-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Zetia (Ezetimibe): Phase na readout est. (NCT07626840)
DESCRIPTION:Zetia (Ezetimibe)\, phase na\, Atherosclerotic Cardiovascular D
 isease.\nStudy: Livalozet Versus High-intensity Statin in Older Patients W
 ith Coronary Artery Disease Undergoing Percutaneous Coronary Intervention\
 nEstimated primary completion: 1 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ezetimibe#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07626840
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605130-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT07605130)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4.\nStudy: Efficacy and Safety Study 
 of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering 
 Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Fac
 torial\, Randomized\, Parallel-Group\, Multicenter Trial\nEstimated primar
 y completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ezetimibe#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07605130
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307989-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Zetia (Ezetimibe): Phase 2 readout est. (NCT07307989)
DESCRIPTION:Zetia (Ezetimibe)\, phase 2\, Atherosclerotic Cardiovascular Di
 sease.\nStudy: Early Statin-Ezetimibe Combination vs. Statin Monotherapy i
 n Stroke With Atherosclerosis\nEstimated primary completion: 31 July 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ezetimibe#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07307989
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799779-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT07799779)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4\, Atherosclerotic Cardiovascular Di
 sease.\nStudy: Early Intensive Lipid-Lowering With Inclisiran for Plaque S
 tabilization in Acute Coronary Syndrome\nEstimated primary completion: Sep
 tember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ezetimib
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 799779
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871604-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20290921
DTEND;VALUE=DATE:20290922
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT07871604)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4\, Atherosclerotic Cardiovascular Di
 sease.\nStudy: Feasibility of Combination Therapy With Low-dose Statin and
  Ezetimibe in Patients With Minimal Subclinical Atherosclerosis\nEstimated
  primary completion: 21 September 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ezetimibe#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07871604
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649240-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Zetia (Ezetimibe): Phase na readout est. (NCT06649240)
DESCRIPTION:Zetia (Ezetimibe)\, phase na.\nStudy: Optimal Target Low-densit
 y Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke\nEstimat
 ed primary completion: September 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ezetimibe#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06649240
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06722521-6695@assetmemo.bio
DTSTAMP:20261121T004503Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Zetia (Ezetimibe): Phase 4 readout est. (NCT06722521)
DESCRIPTION:Zetia (Ezetimibe)\, phase 4.\nStudy: GUIDE-CAC: Statin-Ezetimib
 e Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Cal
 cification\nEstimated primary completion: 30 June 2032. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ezetimibe#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06722521
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
